New research reveals that patients who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds far faster than those who halt traditional lifestyle plans.
Findings released in a prominent medical journal shows that while overweight people can lose a large proportion of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these treatments should be cognizant of the risk of quick weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
That rate of regain means a reversion to original weight within about one and a half years.
Comparing Therapies
The study, which looked at dozens of trials involving over 9,000 of participants, compared the results of these new drugs with conventional dieting.
Scientists note that individuals who shed pounds through lifestyle changes alone usually have a slower creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors suggest the mechanism of the jabs accounts for the heightened weight return.
The injections copy a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating far more likely."
An Ongoing Issue?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals say that, considering the likelihood of weight regain, the therapy is often life-long.
This opinion is reinforced by drug manufacturers, who note that the findings "emphasize the chronic character of obesity," similar to managing diseases like hypertension.
User Experiences
Users who have stopped the jabs report a intense resurgence of cravings.
"It was like a trigger that goes on and you're instantly starving," described one woman.
This difficulty is exacerbated if patients have not developed permanent lifestyle or habit changes during therapy.
Significant Adoption
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among females than men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while the jabs are potent tools for weight loss, they are not a standalone cure and maintained weight loss relies on ongoing behavioural management.
